Back to News
Market Impact: 0.12
Pilatus Biosciences to Present Trials-in-Progress Poster on Phase 1 PLT012 for Solid Tumor Cancers at ESMO 2026
Source: Business Wire
Healthcare & Biotech
Pilatus Biosciences announced it will present a trials-in-progress poster for its Phase 1 PLT012 program in solid-tumor cancers at ESMO 2026. The announcement signals ongoing early-stage clinical development but provides no efficacy, safety, financial, or regulatory data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
- J&J presents patient data on nipocalimab for Sjögren’s disease
- Rent-a-grandchild: Businesses offering companions to elderly grow in India